- Home
- LUCD vs GANX Comparison
LUCD vs GANX Comparison
Compare LUCD & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCD
- GANX
- Stock Information
- Founded
- LUCD 2018
- GANX 2017
- Country
- LUCD United States
- GANX United States
- Employees
- LUCD N/A
- GANX N/A
- Industry
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- LUCD Health Care
- GANX Health Care
- Exchange
- LUCD Nasdaq
- GANX Nasdaq
- Market Cap
- LUCD 51.6M
- GANX 50.9M
- IPO Year
- LUCD 2021
- GANX 2021
- Fundamental
- Price
- LUCD $1.22
- GANX $1.92
- Analyst Decision
- LUCD Strong Buy
- GANX Strong Buy
- Analyst Count
- LUCD 4
- GANX 6
- Target Price
- LUCD $3.63
- GANX $8.33
- AVG Volume (30 Days)
- LUCD 986.1K
- GANX 239.1K
- Earning Date
- LUCD 03-24-2025
- GANX 03-25-2025
- Dividend Yield
- LUCD N/A
- GANX N/A
- EPS Growth
- LUCD N/A
- GANX N/A
- EPS
- LUCD N/A
- GANX N/A
- Revenue
- LUCD $4,189,000.00
- GANX N/A
- Revenue This Year
- LUCD $91.72
- GANX N/A
- Revenue Next Year
- LUCD $139.38
- GANX N/A
- P/E Ratio
- LUCD N/A
- GANX N/A
- Revenue Growth
- LUCD 179.27
- GANX N/A
- 52 Week Low
- LUCD $0.63
- GANX $0.89
- 52 Week High
- LUCD $1.63
- GANX $4.74
- Technical
- Relative Strength Index (RSI)
- LUCD 46.35
- GANX 40.61
- Support Level
- LUCD $1.27
- GANX $1.55
- Resistance Level
- LUCD $1.47
- GANX $2.15
- Average True Range (ATR)
- LUCD 0.16
- GANX 0.27
- MACD
- LUCD -0.04
- GANX -0.05
- Stochastic Oscillator
- LUCD 15.59
- GANX 28.77
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.